TORONTO, ONTARIO — (Marketwired) — 08/29/13 — BioExx Specialty Proteins Ltd. (“BioExx” or the “Company”) (TSX: BXI), today announced that its board of directors (the “Board”) has appointed John MacDonald, currently a director of the Company, to serve as Interim Chief Executive Officer of the Company. The Board wishes to express its gratitude to Chris Schnarr, the previous Chief Executive Officer of the Company, who has also resigned from the Board.
Mr. MacDonald is Managing Director of John MacDonald and Associates, a firm of established accounting and tax professionals he founded in 1989 after several years in senior management positions with the Government of Ontario. Serving in various roles including CEO, Chairman, and Chief Restructuring Officer, Mr. MacDonald has leveraged his leadership and professional experience to lead change and growth strategies at several companies. Mr. MacDonald has been a director of BioExx since April 2008.
About BioExx Specialty Proteins Ltd.
Headquartered in Toronto, Canada, BioExx is focused on the separation of oil and high-value proteins from oilseeds for global food, beverage, nutrition, and other markets. BioExx employs trade secret, patented and patent-pending technologies to enable the improved separation of proteins from oilseeds. BioExx believes that these processes cumulatively have the potential to make a valuable contribution to global food and protein supply while maintaining an environmentally sustainable footprint.
To find out more about BioExx Specialty Proteins Ltd. (TSX: BXI), please visit .
The statements made in this press release include forward-looking statements that involve a number of risks and uncertainties. These statements relate to future events or future performance and reflect management–s current expectations and assumptions. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements, such as the economy, generally, competition in its target markets, the demand for BioExx–s products, the availability of funding, the efficacy of its technology, and the anticipated costs of BioExx–s plant construction and operation. These forward-looking statements are made as of the date hereof and BioExx does not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from BioExx–s expectations and projections.
Contacts:
BioExx Specialty Proteins Ltd.
John MacDonald
Interim Chief Executive Officer
(416) 588-4442